CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

anakinra

Last Updated: November 16, 2020
Result type: Reports
Project Number: SR0662-000
Product Line: Reimbursement Review

Generic Name: anakinra

Brand Name: Kineret

Manufacturer: Swedish Orphan Biovitrum AB

Therapeutic Area: Still's disease

Indications: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.

Manufacturer Requested Reimbursement Criteria1: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: November 16, 2020

Call for patient/clinician input closed: January 15, 2021

Anticipated Date: December 14, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback